稳定型冠心病合并肥胖患者血清Ghrelin nesfatin-1 Obestatin的临床意义

doi:10.3969/j.issn.1006-6233.2021.04.024

摘要
图/表
参考文献
相关文章 (5)

全文: PDF (1348 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究稳定型冠心病合并肥胖患者血清胃饥饿素(Ghrelin)、人新饱食分子蛋白1(nesfatin-1)、肥胖抑制素(Obestatin)的表达水平及临床意义。方法: 选取2018年9月至2020年8月北京朝阳急诊抢救中心收治的206例稳定型冠心病患者为研究对象,依据《中国成人超重和肥胖症预防控制指南》将研究对象分为正常组(87例)、超重组(72例)、肥胖组(47例),检测高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、三酰甘油(TG)、空腹血糖(FBG)水平,采用酶联免疫吸附法(ELISA)检测血清Ghrelin、nesfatin-1、Obestatin水平并进行组间比较;收集患者基本资料;对患者进行冠状动脉造影检查并计算SYNTAX积分;采用Spearman分析血清Ghrelin、nesfatin-1水平与SYNTAX积分相关性;采用Logistic回归模型分析影响稳定型冠心病患者病情严重程度的因素。结果: 正常组、超重组、肥胖组体质量指数(BMI)、LDL-C、TC、SYNTAX积分呈升高趋势(P<0.05),HDL-C、血清Ghrelin、nesfatin-1水平呈降低趋势(P<0.05),血清Obestatin水平差异无统计学意义(P>0.05),三组病变支数差异有统计学意义(P<0.05);Spearman分析结果显示,血清Ghrelin、nesfatin-1水平与SYNTAX积分均呈负相关(r=-0.532,P=0.000;r=-0.630,P=0.000);多因素Logistic回归分析结果显示,BMI、LDL-C、TC均是影响稳定型冠心病患者发生重度病变的独立危险因素(P<0.05),Ghrelin、nesfatin-1是影响稳定型冠心病患者发生重度病变的保护因素(P<0.05)。结论: 稳定型冠心病合并肥胖患者血清Ghrelin、nesfatin-1表达水平与稳定型冠心病患者病情严重程度密切相关,可能成为评估病情的生物学辅助指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	卢青虎
	刘世刚
	张红岩

关键词 ：稳定型冠心病, 肥胖, 胃饥饿素, 人新饱食分子蛋白1, 肥胖抑制素

Abstract：Objective: To investigate the expression levels and significance of serum Ghrelin, nesfatin-1 and Obestatin in patients with stable coronary heart disease complicated with obesity.Methods: A total of 206 patients with stable coronary heart disease (CHD) admitted to Beijing Chaoyang emergency rescue center from September 2018 to August 2020 were selected and divided into normal group (87 cases), overweight group (72 cases) and obesity group (47 cases) according to the Guidelines for Prevention and Control of Overweight and Obesity in Chinese adults, the levels of high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG) and fasting blood glucose (FBG) were measured, the serum levels of Ghrelin, nesfatin-1 and Obestatin were detected by enzyme-linked immunosorbent assay (ELISA); the basic data of patients were collected; coronary angiography was performed and SYNTAX score was calculated; Spearman was used to analyze the correlation between serum Ghrelin, nesfatin-1 levels and SYNTAX score; Logistic regression model was used to analyze the factors influencing the severity of stable coronary heart disease. Results: The BMI, LDL-C, TC and syntac of the normal group, the hyperrecombination group and the obesity group were increased (P<0.05). HDL-C, ghrelin and nesfatin-1 were decreased (P<0.05), and the serum obestatin levels were not statistically significant (P>0.05). And the difference of the number of pathological changes in the three groups was statistically significant (P<0.05). Spearman analysis showed that serum ghrelin and nesfatin-1 levels were negatively correlated with syntax score (r = -0.532, P = 0.000; r = -0.630, P = 0.000). Multivariate logistic regression analysis showed that BMI, LDL-C and TC were independent risk factors for severe lesions in patients with stable coronary heart disease (P<0.05). Ghrelin and nesfatin-1 were protective factors for severe lesions in patients with stable coronary heart disease (P<0.05). Conclusion: The expression levels of serum Ghrelin and nesfatin-1 in patients with stable coronary heart disease and obesity are closely related to the severity of the disease in patients with stable coronary heart disease, and may become biological auxiliary indicators for evaluating the condition.

Key words： Stable coronary heart disease Obesity Ghrelin Nesfatin-1 Obestatin

基金资助:北京市科学技术委员会科研计划项目,(编号:D181100003235019)

引用本文:

卢青虎, 刘世刚, 张红岩. 稳定型冠心病合并肥胖患者血清Ghrelin nesfatin-1 Obestatin的临床意义[J]. 河北医学, 2021, 27(4): 639-644.
LU Qinghu, LIU Shigang, et al. Clinical Significance of Serum Ghrelin, Nesfatin-1 and Obestatin in Patients with Stable Coronary Heart Disease and Obesity. HeBei Med, 2021, 27(4): 639-644.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.04.024 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I4/639

[1] 陶青,邹伟婕,范艳芬,等.冠状动脉周围脂肪直方图参数鉴别急性冠状动脉综合征及稳定性冠心病的价值初探[J].中华放射学杂志,2020,54(3):192~197.
[2] Seulggie C,Kyuwoong K,Min KS,et al.Association of obesity or weight change with coronary heart disease among young adults in South Korea[J].JAMA Intern Med,2018,178(1):1060~1068.
[3] 吴媛媛,陈莉,李翠翠,等.血浆促生长激素释放多肽、脑钠肽水平与急性心肌梗死患者心力衰竭的关系研究[J].实用心脑肺血管病杂志,2020,28(3):40~43.
[4] 程飞,魏云杰,许海军,等.联合检测FT3、Ghrelin、obestatin水平及其与冠心病的相关性[J].心脑血管病防治,2019,19(3):228~230.
[5] 王高华,张楠,王惠玲,等.nesfatin-1的神经内分泌作用研究进展[J].中国临床研究,2018,31(2):261~265.
[6] 刘洋,廖博,魏继棠.血浆CT-1 Ghrelin Lp-PLA2检测在冠心病中的临床价值[J].河北医学,2019,25(12):2108~2112.
[7] 中华人民共和国卫生部疾病控制司.中国成人超重和肥胖症预防控制指南[M].北京:人民卫生出版社,2006.1~2.
[8] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680~694.
[9] 张涛,陈伟.稳定型冠心病患者血清低密度脂蛋白胆固醇和载脂蛋白B浓度与SYNTAX评分的关系[J].岭南心血管病杂志,2020,26(2):148~151,166.
[10] Khaleel EF,Abdel-Aleem GA.Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake,enhancing hepatic adiponectin signaling,and blocking ghrelin acylation[J].Arch Physiol Biochem,2019,125(1):64~78.
[11] 李欣颖,全会标,陈娟,等.Ghrelin通过ERK、PI3K/Akt信号通路拮抗LPS对胰岛β细胞的损伤机制研究[J].国际免疫学杂志,2019,42(1):12~16.
[12] 付鹏宇,龚丽景,朱镕鑫,等.有氧运动对肥胖小鼠胃组织Ghrelin和下丘脑GHSR-1a表达的影响[J].中国运动医学杂志,2019,38(8):685~690.
[13] 鲍礼智,苏婷,郑兴,等.肥胖抑制素与心血管疾病[J].国际心血管病杂志,2019,46(1):22~25.
[14] 范锦勤,翁锡全,徐国琴,等.低氧运动干预肥胖模型大鼠下丘脑Nesfatin-1和Ghrelin水平[J].中国组织工程研究,2020,24(20):3202~3208.
[15] 赵瑛,周立新,李晓龙,等.血清apelin、nesfatin-1与2型糖尿病大血管病变的关系研究[J].河北医药,2019,41(4):607~609.